AIRLINK 75.11 Increased By ▲ 1.41 (1.91%)
BOP 4.90 No Change ▼ 0.00 (0%)
CNERGY 4.43 Decreased By ▼ -0.09 (-1.99%)
DFML 43.15 Decreased By ▼ -1.73 (-3.85%)
DGKC 84.43 Decreased By ▼ -1.07 (-1.25%)
FCCL 21.22 Decreased By ▼ -0.18 (-0.84%)
FFBL 32.40 Decreased By ▼ -0.11 (-0.34%)
FFL 9.52 Decreased By ▼ -0.07 (-0.73%)
GGL 10.15 Decreased By ▼ -0.12 (-1.17%)
HASCOL 7.00 Decreased By ▼ -0.13 (-1.82%)
HBL 114.46 Decreased By ▼ -0.24 (-0.21%)
HUBC 139.40 Increased By ▲ 0.30 (0.22%)
HUMNL 12.12 Decreased By ▼ -0.30 (-2.42%)
KEL 4.95 Decreased By ▼ -0.08 (-1.59%)
KOSM 4.40 Decreased By ▼ -0.05 (-1.12%)
MLCF 37.10 Decreased By ▼ -0.50 (-1.33%)
OGDC 133.85 Decreased By ▼ -2.95 (-2.16%)
PAEL 25.25 Decreased By ▼ -0.14 (-0.55%)
PIBTL 6.64 Decreased By ▼ -0.05 (-0.75%)
PPL 118.90 Decreased By ▼ -2.10 (-1.74%)
PRL 26.35 Decreased By ▼ -0.24 (-0.9%)
PTC 13.90 Decreased By ▼ -0.20 (-1.42%)
SEARL 56.62 Decreased By ▼ -0.68 (-1.19%)
SNGP 66.80 Decreased By ▼ -1.20 (-1.76%)
SSGC 10.35 Decreased By ▼ -0.07 (-0.67%)
TELE 8.34 Decreased By ▼ -0.11 (-1.3%)
TPLP 10.91 Decreased By ▼ -0.07 (-0.64%)
TRG 62.85 Decreased By ▼ -0.49 (-0.77%)
UNITY 26.98 Decreased By ▼ -0.07 (-0.26%)
WTL 1.35 Decreased By ▼ -0.03 (-2.17%)
BR100 7,887 Decreased By -53.5 (-0.67%)
BR30 25,367 Decreased By -280.6 (-1.09%)
KSE100 75,108 Decreased By -409.3 (-0.54%)
KSE30 24,125 Decreased By -152.4 (-0.63%)

Merck & Co Inc said on Friday its experimental COVID-19 pill reduced the risk of hospitalization and death by 30% in a study, according to data from all the patients enrolled in a late-stage study.

The company said the data on the drug molnupiravir, developed with Ridgeback Biotherapeutics, had been submitted to the US Food and Drug Administration ahead of a meeting of its expert advisers on Tuesday.

Britain approves Merck's Covid-19 pill in world first

A planned interim analysis of the data last month showed that 7.3% of those given molnupiravir twice a day for five days were hospitalized and none had died by 29 days after the treatment. That compared with a hospitalization rate of 14.1% for placebo patients.

In the updated data, 6.8% of those given molnupiravir were hospitalized and one person died, while the other placebo group had a hospitalization rate of 9.7%.

Pfizer says antiviral pill cuts risk of severe Covid-19 by 89pc

Comments

Comments are closed.